A Phase 3 interventional study of Lisdexamfetamine Dimesylate (LDX) in ADHD, sponsored by Shire. Completed at 45 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 11th largest by enrollment, is one of 9 that started in 2008, is one of 15 in phase 3, and was the 15th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 8 yrs–198 mo
By country, each count listing its studies:
lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 23
First in 2004; this study’s year is marked. 9 started in 2008.
This study's enrollment of 269 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 48 across the 51 interventional studies. Of the 49 that completed or were terminated, 37 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
57 studies in Attention Deficit Disorder with Hyperactivity by Takeda: none open now, none under way, none of them phase 3. Of 55 finished, 37 (67%) have results posted.
Among the 57 studies in Attention Deficit Disorder with Hyperactivity by Takeda, this one is the 23rd largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2008, is one of 32 in phase 3, and was the 25th registered.
Takeda’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 57 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).
Not Required
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lisdexamfetamine Dimesylate (LDX)
Drug: Lisdexamfetamine Dimesylate (LDX)
optimal dose of 30, 50 or 70 mg once daily
Also known as: Vyvanse
Change From Baseline (From the Antecedent Study, SPD489-305) in the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up to 52 Weeks
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.
Time frame: Baseline and up to 52 weeks
Percent of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I)
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: up to 52 weeks
Change From Baseline (From the Antecedent Study, SPD489-305) in the Youth Quality of Life Instrument-Research Version (YQOL-R) Total Score at up to 52 Weeks
The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.
Time frame: Baseline and Up to 52 weeks
Subjects had to have satisfied all entry criteria for the antecedent study (SPD489-305, NCT00735371) and completed a minimum of 3 weeks of double-blind treatment and reached Visit 3 of the antecedent study (SPD489-305), without experiencing any clinically significant adverse events that would preclude exposure to LDX.
| Milestone | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| Started | 269 |
| Completed | 156 |
| Not completed | 113 |
| Withdrew: Adverse event | 18 |
| Withdrew: Withdrawal by subject | 31 |
| Withdrew: Non-compliance | 16 |
| Withdrew: Lost to follow-up | 25 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Subject moved | 7 |
| Withdrew: Pregnancy | 3 |
| Withdrew: Prohibited medication | 1 |
| Withdrew: Out of town | 1 |
| Withdrew: Misuse and compliance of study drug | 1 |
| Withdrew: Subject sent to boarding school | 1 |
| Withdrew: Met an exclusion criteria | 1 |
| Withdrew: Positive drug screen | 2 |
| Withdrew: Sponsor requested withdrawal | 1 |
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.
| Units on a scale | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| Change From Baseline (From the Antecedent Study, SPD489-305) in the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up to 52 Weeks | -26.2 ± 9.75 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| Percent of participants | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| Percent of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I) | 87.2 |
The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.
| Units on a scale | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| Change From Baseline (From the Antecedent Study, SPD489-305) in the Youth Quality of Life Instrument-Research Version (YQOL-R) Total Score at up to 52 Weeks | 3.9 ± 9.73 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisdexamfetamine Dimesylate (LDX) | — | 10/265 (3.8%) | 230/265 (86.8%) |
| Event | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| SyncopeNervous system disorders | 3/265 |
| AggressionPsychiatric disorders | 2/265 |
| HydroceleCongenital, familial and genetic disorders | 1/265 |
| PneumoniaInfections and infestations | 1/265 |
| Joint SprainInjury, poisoning and procedural complications | 1/265 |
| Pelvic FractureInjury, poisoning and procedural complications | 1/265 |
| Traumatic Liver InjuryInjury, poisoning and procedural complications | 1/265 |
| Wrist FractureInjury, poisoning and procedural complications | 1/265 |
| Syncope VasovagalNervous system disorders | 1/265 |
| Ectopic PregnancyPregnancy, puerperium and perinatal conditions | 1/265 |
| Event | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 58/265 |
| Decreased AppetiteMetabolism and nutrition disorders | 56/265 |
| HeadacheNervous system disorders | 55/265 |
| Weight DecreasedInvestigations | 43/265 |
| IrritabilityGeneral disorders | 33/265 |
| InsomniaPsychiatric disorders | 32/265 |
| NasopharyngitisInfections and infestations | 19/265 |
| InfluenzaInfections and infestations | 18/265 |
| Dry MouthGastrointestinal disorders | 14/265 |
| DizzinessNervous system disorders | 14/265 |
| Age, Continuous(years) | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| Mean | 14.5 ± 1.30 |
| Age, Customized(Participants) | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| 13 to 14 years | 144 |
| 15 to 17 years | 121 |
| Sex: Female, Male(Participants) | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| Female | 78 |
| Male | 187 |
| Region of Enrollment(Participants) | Lisdexamfetamine Dimesylate (LDX) |
|---|---|
| United States | 265 |
Ran from Nov 2008 to primary completion in Apr 2010, 17 months.
Results were first posted in Mar 2011, 11 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 17 months is above that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →